As of June 6, 2025, Charles River Laboratories International Inc (CRL) reports a EV/EBITDA of 16.47.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Charles River Laboratories International Inc's EV/EBITDA to Peers
To better understand Charles River Laboratories International Inc's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Charles River Laboratories International Inc (CRL) | 16.47 |
| Chromadex Corp (CDXC) | 65.29 |
| Innovotech Inc (IOT.V) | 36.63 |
| Qiagen NV (QGEN) | 35.08 |
| Bio Rad Laboratories Inc (BIO) | 27.34 |
| Bruker Corp (BRKR) | 19.72 |
Compared to its competitors, Charles River Laboratories International Inc's EV/EBITDA is about average compared to peers, indicating market valuation in line with industry expectations.